Goldline Pharmaceutical IPO is a book-built issue worth ₹11.61 crore. The IPO consists entirely of a fresh issue of 27 lakh equity shares. The IPO opens for subscription on May 12, 2026, and closes on May 14, 2026. The allotment is expected to be finalised on May 15, 2026, with tentative listing on BSE SME scheduled for May 19, 2026.
The IPO is priced in a band of ₹41 - ₹43 per share. Retail investors must apply for a minimum of 2 lots comprising 6,000 shares, requiring an investment of ₹2,58,000 at the upper price band. HNI investors must apply for a minimum of 3 lots (9,000 shares), amounting to ₹3,87,000.
Cumulative Capital Private Limited is the book-running lead manager to the issue, and Bigshare Services Private Limited is the registrar.
For detailed information on company financials, business operations, and associated risks, investors are advised to refer to the Goldline Pharmaceutical IPO RHP.
